SEC Issues Charges on Pharma Insider Trading
The U.S. Securities and Exchange Commission (SEC) recently charged two men from Rhode Island with insider trading in the securities of deal targets being pursued by the pharmaceutical company where one of them worked. The SEC alleged that Michael J.…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The U.S. Securities and Exchange Commission (SEC) recently charged two men from Rhode Island with insider trading in the securities of deal targets being pursued by the pharmaceutical company where one of them worked.
The SEC alleged that Michael J. Maciocio obtained confidential clinical and business data about other pharmaceutical firms being considered by his company for potential acquisitions and business relationships, and that he used this nonpublic information to trade in their stocks.
Maciocio made roughly $116,000 in illegal profits trading in such pharmaceutical companies as Medivation Inc. (NASDAQ: MDVN), Ardea Biosciences, and Furiex Pharmaceuticals.
[nativounit]
The agency further alleged that Maciocio illegally tipped his childhood friend, stockbroker David P. Hobson, who utilized the nonpublic information to realize at least $187,000 in illicit trading profits for himself and $145,000 for his customers.
Joseph G. Sansone, Co-Chief of the SEC Enforcement Division’s Market Abuse Unit, commented in the report:
We allege that Maciocio and Hobson engaged in a multi-year insider trading scheme by repeatedly using the confidential information of Maciocio’s employer to place illicit trades. Given his years of experience in the securities industry, Hobson’s misuse of this highly sensitive corporate deal information represents an especially egregious violation of the law.
In a parallel action, the U.S. Attorney’s Office for the Southern District of New York today announced criminal charges against Maciocio and Hobson.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
